Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from AstraZeneca

Up 1,000% in 2024, Wall Street Believes This Growth Stock Can Still Skyrocket

This biotech stock is a promising buy, but it does come with risks.

Barchart

Daily pill on NHS offers new hope for hundreds with lung cancer

Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery

The Independent UK

Well-known medics to appear in front of UK Covid probe

Module four of the inquiry is looking at the development and rollout of vaccines in the UK.

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

GSK to buy US cancer drug firm IDRx for up to $1.15bn

Massachusetts-based company is working on new treatments for gastrointestinal cancers

The Guardian - UK

From the Beatles to biologics – how Liverpool became a life science hotspot

The city has a long history with tropical medicine and is now home to one of the largest biotech clusters in Europe

The Guardian - UK

Breast cancer drug Lynparza reduces risk of death by 28% in patients diagnosed early, clinical trial shows

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

Fortune

After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer

AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression outcomes in treated patients.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Astrazeneca Appoints New China Head Amid Investigation Concerns

AstraZeneca appoints Iskra Reic as new head of China operations amid investigations and challenges in the pharmaceutical industry in China.

Top News

First new treatment for asthma and COPD in half a century – new study

Every 30 seconds, someone in the world will experience a flare-up of their asthma or chronic obstructive pulmonary disease (COPD) symptoms. For decades, the standard treatment for these potentially life-threatening episodes has remained unchanged – treatment with steroids, such as prednisolone.

The Conversation

Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch

Here's why Eli Lilly, Pfizer, and AstraZeneca are biotech stocks worth considering, with strong pipelines and growth potential beyond vaccines.

MarketBeat

AstraZeneca's Truqap Demonstrates Progress in Advanced Prostate Cancer Treatment

Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca's Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically

Benzinga

Breast cancer drug blocked for NHS use in England and Wales after talks collapse

National Institute for Health and Care Excellence unable to reach price agreement with manufacturers of Enhertu

The Guardian - UK

Breast cancer drug blocked for NHS use as price talks break down for third time

Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name Enhertu.

Evening Standard

Breast cancer drug blocked for NHS use as price talks break down – leaving charities ‘beyond devastated’

Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name Enhertu

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Pharma shares hit as Trump picks RFK Jr to lead health department

Choice of vaccine critic knocks some of world’s biggest drugmakers including Moderna, AstraZeneca and GSK

The Guardian - UK

AstraZeneca’s numbers are good but trouble in China could drag it down

Profits beat forecasts but a 17% fall in share price since executives were detained by Beijing may be hard to shake

Investors Business Daily

AstraZeneca Reverses As Beat And Raise Outweighs Drug Smuggling Claims

AstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, and AstraZeneca stock rose despite a criminal probe in China.

The Guardian - UK

AstraZeneca says it takes China investigation ‘very seriously’

UK’s biggest pharmaceutical company ‘committed to China’ as it raises 2024 profit forecast and announces $3.5bn US investment

Get all your
news in one place.

100’s of premium titles.
One news app.

Evening Standard

AstraZeneca boss says firm takes China probe ‘very seriously’

The group’s shares have tumbled after it emerged that the firm’s China president has been detained as Chinese authorities deepen their investigation.

Evening Standard

FTSE 100 Live 12 November: Vodafone and AstraZeneca results fail to revive shares, Metro Bank fined £16m

Cracks are appearing in the labour market after the unemployment rate today rose to 4.3%.

International Business Times

Pharma Giant AstraZeneca Says China Chief Detained

Leon Wang, president of AstraZeneca China, "has been detained", a representative of the firm's global media team said in an email to AFP.

The Guardian - UK

AstraZeneca shares tumble after reports China unit is linked to insurance fraud

Pharmaceutical’s weight loss pill described as ‘underwhelming’, also piling pressure on share price

Evening Standard

AstraZeneca drags on FTSE as Wall Street positive amid US election voting

The FTSE 100 finished 11.85 points, or 0.14%, lower to end the day at 8,172.39.

The Guardian - UK

OBR moving to ‘trust but verify’ relationship with Treasury after ‘black hole’ row – as it happened

Rolling coverage of the latest economic and financial news

Investors Business Daily

Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat

Viking Therapeutics reported strong weight loss for higher doses of its experimental obesity drug.

1 2 3 4 5

People

Margherita Della Valle

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.